{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:48:24Z","timestamp":1787003304489,"version":"build-2736575974"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Genom. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The germline genetic susceptibility to adult glioblastoma remains unclear. With the option of broad molecular testing, it is crucial that clinicians are aware of the a priori probability of finding germline predisposition in glioblastoma patients. Here, we studied the genetic predisposition to adult glioblastoma using paired tumor-normal WGS data in an unselected, average cohort of 92 glioma WHO grade 4 patients. In 10 patients (11%), 12 Pathogenic Germline Variants (PGVs) were found in genes strongly associated with familial glioblastoma (\n                    <jats:italic>MSH6<\/jats:italic>\n                    (3x),\n                    <jats:italic>PMS2<\/jats:italic>\n                    (5x),\n                    <jats:italic>MSH2<\/jats:italic>\n                    ,\n                    <jats:italic>NF1<\/jats:italic>\n                    ,\n                    <jats:italic>BRCA1<\/jats:italic>\n                    ) or medulloblastoma (\n                    <jats:italic>SUFU<\/jats:italic>\n                    ). In six of these patients (60%), causality was supported by a second (somatic) event and\/or a matching genome-wide mutational signature. Thus, germline predisposition does play a role in the development of adult glioblastoma, with mismatch repair deficiency being the main mechanism. Our results also highlight the benefits of tumor-normal WGS for glioblastoma patients and their families, beyond identifying actionable mutations for therapy.\n                  <\/jats:p>","DOI":"10.1038\/s41525-025-00526-z","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:38:48Z","timestamp":1761824328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Whole genome sequencing-based analysis of genetic predisposition to adult glioblastoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Mark P.","family":"van Opijnen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin R.","family":"van Valkengoed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"de Ligt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip Y. F.","family":"de Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marike L. D.","family":"Broekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Cuppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roelof","family":"Koster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"526_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987\u2013996 (2005).","journal-title":"N. Engl. J. Med."},{"key":"526_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459\u2013466 (2009).","journal-title":"Lancet Oncol."},{"key":"526_CR3","doi-asserted-by":"crossref","unstructured":"Akgul, S. et al. Intratumoural heterogeneity underlies distinct therapy responses and treatment resistance in glioblastoma. Cancers 11, 190 (2019).","DOI":"10.3390\/cancers11020190"},{"key":"526_CR4","first-page":"vdab177","volume":"4","author":"WS van de Geer","year":"2022","unstructured":"van de Geer, W. S. et al. Landscape of driver gene events, biomarkers, and druggable targets identified by whole-genome sequencing of glioblastomas. Neurooncol. Adv. 4, vdab177 (2022).","journal-title":"Neurooncol. Adv."},{"key":"526_CR5","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396\u20131401 (2014).","journal-title":"Science"},{"key":"526_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/neuros\/nyaa305","volume":"88","author":"AM Khalafallah","year":"2021","unstructured":"Khalafallah, A. M. et al. \u2018Zooming in\u2019 on glioblastoma: understanding tumor heterogeneity and its clinical implications in the era of single-cell ribonucleic acid sequencing. Neurosurgery 88, 477\u2013486 (2021).","journal-title":"Neurosurgery"},{"key":"526_CR7","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jmoldx.2021.04.011","volume":"23","author":"P Roepman","year":"2021","unstructured":"Roepman, P. et al. Clinical validation of whole genome sequencing for cancer diagnostics. J. Mol. Diagn. 23, 816\u2013833 (2021).","journal-title":"J. Mol. Diagn."},{"key":"526_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/path.5988","volume":"258","author":"KG Samsom","year":"2022","unstructured":"Samsom, K. G. et al. Feasibility of whole-genome sequencing-based tumor diagnostics in routine pathology practice. J. Pathol. 258, 179\u2013188 (2022).","journal-title":"J. Pathol."},{"key":"526_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-022-01343-4","volume":"15","author":"MP van Opijnen","year":"2022","unstructured":"van Opijnen, M. P. et al. Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics-a prospective multicenter cohort study. BMC Med. Genomics 15, 233 (2022).","journal-title":"BMC Med. Genomics"},{"key":"526_CR10","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.18.00358","volume":"37","author":"E Castro","year":"2019","unstructured":"Castro, E. et al. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 37, 490\u2013503 (2019).","journal-title":"J. Clin. Oncol."},{"key":"526_CR11","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt, A. N. J. et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N. Engl. J. Med. 384, 2394\u20132405 (2021).","journal-title":"N. Engl. J. Med"},{"key":"526_CR12","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton, J. K. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N. Engl. J. Med. 379, 753\u2013763 (2018).","journal-title":"N. Engl. J. Med"},{"key":"526_CR13","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1038\/s41591-023-02544-9","volume":"29","author":"EC Harrold","year":"2023","unstructured":"Harrold, E. C. et al. Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade. Nat. Med. 29, 2458\u20132463 (2023).","journal-title":"Nat. Med."},{"key":"526_CR14","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1038\/s41591-024-03250-w","volume":"30","author":"PGM de Gooyer","year":"2024","unstructured":"de Gooyer, P. G. M. et al. Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial. Nat. Med. 30, 3284\u20133290 (2024).","journal-title":"Nat. Med."},{"key":"526_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J. Clin. Oncol. 38, 1\u201310 (2020).","journal-title":"J. Clin. Oncol."},{"key":"526_CR16","doi-asserted-by":"publisher","first-page":"113253","DOI":"10.1016\/j.ejca.2023.113253","volume":"192","author":"JH Yu","year":"2023","unstructured":"Yu, J. H. et al. Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients. Eur. J. Cancer 192, 113253 (2023).","journal-title":"Eur. J. Cancer"},{"key":"526_CR17","doi-asserted-by":"publisher","first-page":"5741","DOI":"10.1002\/jcp.27464","volume":"234","author":"M Mahdavi","year":"2019","unstructured":"Mahdavi, M. et al. Hereditary breast cancer; Genetic penetrance and current status with BRCA. J. Cell Physiol. 234, 5741\u20135750 (2019).","journal-title":"J. Cell Physiol."},{"key":"526_CR18","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1053\/j.gastro.2010.01.054","volume":"138","author":"KW Jasperson","year":"2010","unstructured":"Jasperson, K. W., Tuohy, T. M., Neklason, D. W. & Burt, R. W. Hereditary and familial colon cancer. Gastroenterology 138, 2044\u20132058 (2010).","journal-title":"Gastroenterology"},{"key":"526_CR19","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/ajcp\/aqaa172","volume":"155","author":"CK Gestrich","year":"2021","unstructured":"Gestrich, C. K. et al. Molecular profiling of pediatric and adult glioblastoma. Am. J. Clin. Pathol. 155, 606\u2013614 (2021).","journal-title":"Am. J. Clin. Pathol."},{"key":"526_CR20","doi-asserted-by":"publisher","first-page":"eade2675","DOI":"10.1126\/sciadv.ade2675","volume":"9","author":"DJ Choi","year":"2023","unstructured":"Choi, D. J. et al. The genomic landscape of familial glioma. Sci. Adv. 9, eade2675 (2023).","journal-title":"Sci. Adv."},{"key":"526_CR21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/oxfordjournals.aje.a009154","volume":"145","author":"M Wrensch","year":"1997","unstructured":"Wrensch, M. et al. Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. Am. J. Epidemiol. 145, 581\u2013593 (1997).","journal-title":"Am. J. Epidemiol."},{"key":"526_CR22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S1470-2045(09)70076-2","volume":"10","author":"K Hemminki","year":"2009","unstructured":"Hemminki, K., Tretli, S., Sundquist, J., Johannesen, T. B. & Granstrom, C. Familial risks in nervous-system tumours: a histology-specific analysis from Sweden and Norway. Lancet Oncol. 10, 481\u2013488 (2009).","journal-title":"Lancet Oncol."},{"key":"526_CR23","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.ejca.2012.11.009","volume":"49","author":"S Sadetzki","year":"2013","unstructured":"Sadetzki, S. et al. Description of selected characteristics of familial glioma patients - results from the Gliogene Consortium. Eur. J. Cancer 49, 1335\u20131345 (2013).","journal-title":"Eur. J. Cancer"},{"key":"526_CR24","doi-asserted-by":"publisher","first-page":"7568","DOI":"10.1158\/0008-5472.CAN-11-0013","volume":"71","author":"S Shete","year":"2011","unstructured":"Shete, S. et al. Genome-wide high-density SNP linkage search for glioma susceptibility loci: results from the gliogene consortium. Cancer Res. 71, 7568\u20137575 (2011).","journal-title":"Cancer Res."},{"key":"526_CR25","first-page":"10","volume":"3","author":"T Rice","year":"2016","unstructured":"Rice, T. et al. Understanding inherited genetic risk of adult glioma - a review. Neurooncol. Pract. 3, 10\u201316 (2016).","journal-title":"Neurooncol. Pract."},{"key":"526_CR26","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/neuonc\/nou087","volume":"16","author":"QT Ostrom","year":"2014","unstructured":"Ostrom, Q. T. et al. The epidemiology of glioma in adults: a \u2018state of the science\u2019 review. Neuro Oncol. 16, 896\u2013913 (2014).","journal-title":"Neuro Oncol."},{"key":"526_CR27","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1038\/s41436-019-0536-8","volume":"21","author":"NAJ Ryan","year":"2019","unstructured":"Ryan, N. A. J. et al. The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis. Genet. Med. 21, 2167\u20132180 (2019).","journal-title":"Genet. Med."},{"key":"526_CR28","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/jnci\/dju384","volume":"107","author":"MN Bainbridge","year":"2015","unstructured":"Bainbridge, M. N. et al. Germline mutations in shelterin complex genes are associated with familial glioma. J. Natl. Cancer Inst. 107, 384 (2015).","journal-title":"J. Natl. Cancer Inst."},{"key":"526_CR29","first-page":"482","volume":"10","author":"MF McDonald","year":"2023","unstructured":"McDonald, M. F. et al. Prevalence of pathogenic germline variants in adult-type diffuse glioma. Neurooncol. Pract. 10, 482\u2013490 (2023).","journal-title":"Neurooncol. Pract."},{"key":"526_CR30","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/neuonc\/noy119","volume":"20","author":"DI Jacobs","year":"2018","unstructured":"Jacobs, D. I. et al. Elucidating the molecular pathogenesis of glioma: integrated germline and somatic profiling of a familial glioma case series. Neuro Oncol. 20, 1625\u20131633 (2018).","journal-title":"Neuro Oncol."},{"key":"526_CR31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1054\/bjoc.2000.1612","volume":"84","author":"B Malmer","year":"2001","unstructured":"Malmer, B. et al. Genetic epidemiology of glioma. Br. J. Cancer 84, 429\u2013434 (2001).","journal-title":"Br. J. Cancer"},{"key":"526_CR32","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/1098-2272(200102)20:2<258::AID-GEPI8>3.0.CO;2-N","volume":"20","author":"M de Andrade","year":"2001","unstructured":"de Andrade, M. et al. Segregation analysis of cancer in families of glioma patients. Genet Epidemiol. 20, 258\u2013270 (2001).","journal-title":"Genet Epidemiol."},{"key":"526_CR33","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cancergen.2012.10.009","volume":"205","author":"ML Goodenberger","year":"2012","unstructured":"Goodenberger, M. L. & Jenkins, R. B. Genetics of adult glioma. Cancer Genet. 205, 613\u2013621 (2012).","journal-title":"Cancer Genet."},{"key":"526_CR34","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/ng.3823","volume":"49","author":"BS Melin","year":"2017","unstructured":"Melin, B. S. et al. Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat. Genet. 49, 789\u2013794 (2017).","journal-title":"Nat. Genet."},{"key":"526_CR35","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","volume":"173","author":"KA Hoadley","year":"2018","unstructured":"Hoadley, K. A. et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173, 291\u2013304 e6 (2018).","journal-title":"Cell"},{"key":"526_CR36","doi-asserted-by":"publisher","first-page":"101032","DOI":"10.1016\/j.gim.2023.101032","volume":"26","author":"R Koster","year":"2024","unstructured":"Koster, R. et al. Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnostics. Genet Med. 26, 101032 (2024).","journal-title":"Genet Med"},{"key":"526_CR37","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1001\/jamaoncol.2020.0197","volume":"6","author":"L Mirabello","year":"2020","unstructured":"Mirabello, L. et al. Frequency of pathogenic germline variants in cancer-susceptibility genes in patients with osteosarcoma. JAMA Oncol. 6, 724\u2013734 (2020).","journal-title":"JAMA Oncol."},{"key":"526_CR38","first-page":"5571","volume":"11","author":"H Liao","year":"2021","unstructured":"Liao, H. et al. Prevalence and spectrum of germline cancer susceptibility gene variants and somatic second hits in colorectal cancer. Am. J. Cancer Res. 11, 5571\u20135580 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"526_CR39","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","volume":"581","author":"KJ Karczewski","year":"2020","unstructured":"Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434\u2013443 (2020).","journal-title":"Nature"},{"key":"526_CR40","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12929-024-01056-z","volume":"31","author":"MP Silva","year":"2024","unstructured":"Silva, M. P. et al. BUB1B monoallelic germline variants contribute to prostate cancer predisposition by triggering chromosomal instability. J. Biomed. Sci. 31, 74 (2024).","journal-title":"J. Biomed. Sci."},{"key":"526_CR41","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","volume":"173","author":"KL Huang","year":"2018","unstructured":"Huang, K. L. et al. Pathogenic germline variants in 10,389 adult cancers. Cell 173, 355\u2013370.e14 (2018).","journal-title":"Cell"},{"key":"526_CR42","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller, M. et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat. Rev. Clin. Oncol. 18, 170\u2013186 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"526_CR43","doi-asserted-by":"publisher","first-page":"iii93","DOI":"10.1093\/annonc\/mdu050","volume":"25","author":"R Stupp","year":"2014","unstructured":"Stupp, R. et al. High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25, iii93\u2013iii101 (2014).","journal-title":"Ann. Oncol."},{"key":"526_CR44","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/JCO.21.02036","volume":"40","author":"NA Mohile","year":"2022","unstructured":"Mohile, N. A. et al. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. J. Clin. Oncol. 40, 403\u2013426 (2022).","journal-title":"J. Clin. Oncol."},{"key":"526_CR45","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/neuonc\/noad008","volume":"25","author":"D Capper","year":"2023","unstructured":"Capper, D. et al. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. Neuro Oncol. 25, 813\u2013826 (2023).","journal-title":"Neuro Oncol."},{"key":"526_CR46","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11060-024-04568-8","volume":"166","author":"MP van Opijnen","year":"2024","unstructured":"van Opijnen, M. P. et al. Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting. J. Neurooncol. 166, 485\u2013492 (2024).","journal-title":"J. Neurooncol."},{"key":"526_CR47","doi-asserted-by":"publisher","first-page":"e2100516","DOI":"10.1200\/PO.21.00516","volume":"6","author":"ED Esplin","year":"2022","unstructured":"Esplin, E. D. et al. Universal germline genetic testing for hereditary cancer syndromes in patients with solid tumor cancer. JCO Precis. Oncol. 6, e2100516 (2022).","journal-title":"JCO Precis. Oncol."},{"key":"526_CR48","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","volume":"7","author":"NJ Samadder","year":"2021","unstructured":"Samadder, N. J. et al. Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. JAMA Oncol. 7, 230\u2013237 (2021).","journal-title":"JAMA Oncol."},{"key":"526_CR49","doi-asserted-by":"publisher","first-page":"e2213070","DOI":"10.1001\/jamanetworkopen.2022.13070","volume":"5","author":"TA Yap","year":"2022","unstructured":"Yap, T. A. et al. Prevalence of germline findings among tumors from cancer types lacking hereditary testing guidelines. JAMA Netw. Open 5, e2213070 (2022).","journal-title":"JAMA Netw. Open"},{"key":"526_CR50","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1001\/jamaoncol.2015.5208","volume":"2","author":"KA Schrader","year":"2016","unstructured":"Schrader, K. A. et al. Germline variants in targeted tumor sequencing using matched normal DNA. JAMA Oncol. 2, 104\u2013111 (2016).","journal-title":"JAMA Oncol."},{"key":"526_CR51","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1200\/JCO.22.02833","volume":"41","author":"V Subbiah","year":"2023","unstructured":"Subbiah, V. & Kurzrock, R. Universal Germline and tumor genomic testing needed to win the war against cancer: genomics is the diagnosis. J. Clin. Oncol. 41, 3100\u20133103 (2023).","journal-title":"J. Clin. Oncol."},{"key":"526_CR52","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jama.2017.11137","volume":"318","author":"D Mandelker","year":"2017","unstructured":"Mandelker, D. et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA 318, 825\u2013835 (2017).","journal-title":"JAMA"},{"key":"526_CR53","doi-asserted-by":"crossref","unstructured":"Shore, N. et al. Implementation of universal germline genetic testing into standard of care for patients with prostate cancer: the time is now. JCO Oncol. Pract. 21, 747\u2013753 (2024).","DOI":"10.1200\/OP-24-00626"},{"key":"526_CR54","doi-asserted-by":"crossref","unstructured":"Perkins, A. T. et al. Universal germline testing of unselected cancer patients detects pathogenic variants missed by standard guidelines without increasing healthcare costs. Cancers (Basel) 13, 5612 (2021).","DOI":"10.3390\/cancers13225612"},{"key":"526_CR55","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/JU.0000000000004089","volume":"212","author":"MM Choudry","year":"2024","unstructured":"Choudry, M. M. et al. Germline pathogenic variants identified in patients with genitourinary malignancies undergoing universal testing: a multisite single-institution prospective study. J. Urol. 212, 590\u2013599 (2024).","journal-title":"J. Urol."},{"key":"526_CR56","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank, C. U. et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N. Engl. J. Med. 391, 1696\u20131708 (2024).","journal-title":"N. Engl. J. Med."},{"key":"526_CR57","doi-asserted-by":"publisher","unstructured":"Bartkowiak, T. et al. Pembrolizumab alters the tumor immune landscape in a patient with dMMR glioblastoma. medRxiv https:\/\/doi.org\/10.1101\/2023.12.08.23299732 (2023).","DOI":"10.1101\/2023.12.08.23299732"},{"key":"526_CR58","doi-asserted-by":"crossref","unstructured":"Arrieta, V. A. et al. Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. J. Clin. Invest. 133, e163447 (2023).","DOI":"10.1172\/JCI163447"},{"key":"526_CR59","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","volume":"25","author":"J Zhao","year":"2019","unstructured":"Zhao, J. et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat. Med. 25, 462\u2013469 (2019).","journal-title":"Nat. Med."},{"key":"526_CR60","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","volume":"25","author":"TF Cloughesy","year":"2019","unstructured":"Cloughesy, T. F. et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat. Med. 25, 477\u2013486 (2019).","journal-title":"Nat. Med."},{"key":"526_CR61","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1158\/2159-8290.CD-16-0575","volume":"6","author":"TM Johanns","year":"2016","unstructured":"Johanns, T. M. et al. Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discov. 6, 1230\u20131236 (2016).","journal-title":"Cancer Discov."},{"key":"526_CR62","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11060-018-2955-9","volume":"140","author":"RV Lukas","year":"2018","unstructured":"Lukas, R. V. et al. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J. Neurooncol. 140, 317\u2013328 (2018).","journal-title":"J. Neurooncol."},{"key":"526_CR63","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/neuonc\/noab005","volume":"23","author":"X Guo","year":"2021","unstructured":"Guo, X., Wang, S., Wang, Y. & Ma, W. Anti-PD-1 plus anti-VEGF therapy in multiple intracranial metastases of a hypermutated, IDH wild-type glioblastoma. Neuro Oncol. 23, 699\u2013701 (2021).","journal-title":"Neuro Oncol."},{"key":"526_CR64","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41591-021-01581-6","volume":"28","author":"A Das","year":"2022","unstructured":"Das, A. et al. Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nat. Med. 28, 125\u2013135 (2022).","journal-title":"Nat. Med."},{"key":"526_CR65","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","volume":"34","author":"E Bouffet","year":"2016","unstructured":"Bouffet, E. et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J. Clin. Oncol. 34, 2206\u20132211 (2016).","journal-title":"J. Clin. Oncol."},{"key":"526_CR66","doi-asserted-by":"publisher","first-page":"100866","DOI":"10.1016\/j.gim.2023.100866","volume":"25","author":"DT Miller","year":"2023","unstructured":"Miller, D. T. et al. ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 25, 100866 (2023).","journal-title":"Genet. Med."},{"key":"526_CR67","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/humu.20880","volume":"29","author":"SE Plon","year":"2008","unstructured":"Plon, S. E. et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum. Mutat. 29, 1282\u20131291 (2008).","journal-title":"Hum. Mutat."},{"key":"526_CR68","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"526_CR69","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.ajhg.2024.07.013","volume":"111","author":"MT Parsons","year":"2024","unstructured":"Parsons, M. T. et al. Evidence-based recommendations for gene-specific ACMG\/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 variant curation expert panel. Am. J. Hum. Genet 111, 2044\u20132058 (2024).","journal-title":"Am. J. Hum. Genet"},{"key":"526_CR70","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature26000","volume":"555","author":"D Capper","year":"2018","unstructured":"Capper, D. et al. DNA methylation-based classification of central nervous system tumours. Nature 555, 469\u2013474 (2018).","journal-title":"Nature"},{"key":"526_CR71","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00401-023-02654-1","volume":"147","author":"S Hadad","year":"2023","unstructured":"Hadad, S. et al. \u2018De novo replication repair deficient glioblastoma, IDH-wildtype\u2019 is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade. Acta Neuropathol. 147, 3 (2023).","journal-title":"Acta Neuropathol."},{"key":"526_CR72","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","volume":"575","author":"P Priestley","year":"2019","unstructured":"Priestley, P. et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature 575, 210\u2013216 (2019).","journal-title":"Nature"},{"key":"526_CR73","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/bioinformatics\/btt755","volume":"30","author":"B Niu","year":"2014","unstructured":"Niu, B. et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics 30, 1015\u20131016 (2014).","journal-title":"Bioinformatics"},{"key":"526_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15180","volume":"8","author":"I Cortes-Ciriano","year":"2017","unstructured":"Cortes-Ciriano, I., Lee, S., Park, W.-Y., Kim, T.-M. & Park, P. J. A molecular portrait of microsatellite instability across multiple cancers. Nat. Commun. 8, 15180 (2017).","journal-title":"Nat. Commun."},{"key":"526_CR75","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/s41596-023-00933-5","volume":"19","author":"KG Samsom","year":"2024","unstructured":"Samsom, K. G. et al. Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice. Nat. Protoc. 19, 700\u2013726 (2024).","journal-title":"Nat. Protoc."},{"key":"526_CR76","unstructured":"van Putten, J. et al. Clinical application of tumour whole genome sequencing in routine molecular diagnostics for solid cancer patients. Res. Sq. 56, 1856\u20131868 (2025)."},{"key":"526_CR77","unstructured":"Vereniging Klinische Genetica Nederland (VKGN). Tabel 3: Leidraad voor verwijzing na DNA-onderzoek in (tumor)weefsel. Available at https:\/\/artsengenetica.nl\/sites\/default\/files\/tabel-3-versie-januari-2024.pdf (2024)."},{"key":"526_CR78","doi-asserted-by":"crossref","unstructured":"Ritter, D. I. et al. A case for expert curation: an overview of cancer curation in the Clinical Genome Resource (ClinGen). Cold Spring Harb. Mol. Case Stud. 5, a004739 (2019).","DOI":"10.1101\/mcs.a004739"},{"key":"526_CR79","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.ajhg.2021.06.020","volume":"108","author":"Z Stark","year":"2021","unstructured":"Stark, Z. et al. Scaling national and international improvement in virtual gene panel curation via a collaborative approach to discordance resolution. Am. J. Hum. Genet. 108, 1551\u20131557 (2021).","journal-title":"Am. J. Hum. Genet."},{"key":"526_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02423-x","volume":"22","author":"DL Cameron","year":"2021","unstructured":"Cameron, D. L. et al. GRIDSS2: comprehensive characterisation of somatic structural variation using single breakend variants and structural variant phasing. Genome Biol. 22, 202 (2021).","journal-title":"Genome Biol."},{"key":"526_CR81","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062\u2013D1067 (2018).","journal-title":"Nucleic Acids Res."},{"key":"526_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren, W. et al. The EnsEmbl Variant Effect Predictor. Genome Biol. 17, 122 (2016).","journal-title":"Genome Biol."},{"key":"526_CR83","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","volume":"83","author":"I de Bruijn","year":"2023","unstructured":"de Bruijn, I. et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. Cancer Res. 83, 3861\u20133867 (2023).","journal-title":"Cancer Res."},{"key":"526_CR84","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).","journal-title":"Sci. Signal."},{"key":"526_CR85","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"526_CR86","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/mgg3.145","volume":"3","author":"HM van der Klift","year":"2015","unstructured":"van der Klift, H. M. et al. Splicing analysis for exonic and intronic mismatch repair gene variants associated with Lynch syndrome confirms high concordance between minigene assays and patient RNA analyses. Mol. Genet. Genom. Med. 3, 327\u2013345 (2015).","journal-title":"Mol. Genet. Genom. Med."},{"key":"526_CR87","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1399-0004.2011.01635.x","volume":"80","author":"PC Johannesma","year":"2011","unstructured":"Johannesma, P. C. et al. Childhood brain tumours due to germline bi-allelic mismatch repair gene mutations. Clin. Genet. 80, 243\u2013255 (2011).","journal-title":"Clin. Genet."}],"container-title":["npj Genomic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41525-025-00526-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41525-025-00526-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41525-025-00526-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:06:45Z","timestamp":1761829605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41525-025-00526-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["526"],"URL":"https:\/\/doi.org\/10.1038\/s41525-025-00526-z","relation":{},"ISSN":["2056-7944"],"issn-type":[{"value":"2056-7944","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}